Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NKT3964 + Paclitaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NKT3964 | NKT 3964|NKT-3964 | CDK2 Inhibitor 32 | NKT3964 is a proteolysis-targeted chimera (PROTAC) that targets CDK2 for degradation, potentially resulting in decreased tumor cell proliferation and antitumor activity (Eur J Cancer 211 (2024): 114453). | |
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06586957 | Phase I | NKT3964 Doxorubicin + NKT3964 NKT3964 + Paclitaxel | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |